Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences of California (PACB) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.71, marking a -1.16% move from the previous day.
PacBio Stock Up on New FFPE Workflow Boosting Cancer Sequencing
PACB stock rises after unveiling a new FFPE workflow with Covaris, boosting HiFi sequencing accuracy and unlocking insights from archived tumor samples.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.6, marking a +1.91% move from the previous day.
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.44, moving +1.41% from the previous trading session.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ongoing purchasing cycle challenges.
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago.
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $2.26, indicating a -4.64% shift from the previous trading day.
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation
Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving margin improvements. Non-GAAP gross margin hit 42% in Q3, with management attributing gains to a favorable mix shift and yield improvements, notably from multi-use SMRT Cells. Cash burn is materially lower, with year-end cash at $279.5M and Q3 burn around $16M, supporting the company's path toward self-funding.
Pacific Biosciences of California (PACB) Stock Dips While Market Gains: Key Facts
Pacific Biosciences of California (PACB) closed the most recent trading day at $2.58, moving 3.37% from the previous trading session.
